Episode 51: New antibodies, vaccines, and our portfolio companies Cettire, Futu, and Camplify report episode artwork

EPISODE · Sep 2, 2021 · 24 MIN

Episode 51: New antibodies, vaccines, and our portfolio companies Cettire, Futu, and Camplify report

from Frazis Capital Podcast · host Michael Frazis

Timestamps 0:15 Introduction to our strategy 2:55 How a company can lose money and still create value 4:38 Avoiding ‘deep value’ traps 5:30 Update on 2021 fund performance 6:50 How we’re investing in China 9:00 Update on FUTU’s Q2 results and why we bought more 12:18 Recently approved antibodies for COVID-19 – cause for optimism? 16:23 Update on Cettire’s FY21 results 18:03 How we evaluate business ‘quality’ 19:00 Update on Camplify’s FY21 results 21:18 Question: thoughts on Digital Turbine 22:39 Question: thoughts on the recent Square and Afterpay deal

Episode metadata supplied by the publisher feed · Published Sep 2, 2021

Embed this episode

Ready to play

Episode 51: New antibodies, vaccines, and our portfolio companies Cettire, Futu, and Camplify report

0:00 24:22

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Frazis Capital Podcast?

This episode is 24 minutes long.

When was this Frazis Capital Podcast episode published?

This episode was published on September 2, 2021.

Can I download this Frazis Capital Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!